FORA Capital’s Viridian Therapeutics VRDN Stock Holding History

FORA Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,381	Closed	-$276K	–	610
2025 Q4	$276K	Buy	+9,381	New	+$257K	0.03%	373

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FORA Capital's VRDN Position: Q1 2026 in Review

FORA Capital sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 9,381 shares — an estimated $276K sold.

FORA Capital first reported a position in VRDN in Q4 2025 and held it in 1 quarter. The position peaked at $276K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

FORA Capital reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
FORA Capital sold 9,381 Viridian Therapeutics shares in Q1 2026, an estimated $276K.
FORA Capital first reported a position in Viridian Therapeutics in Q4 2025 and held it in 1 quarter.
FORA Capital's Viridian Therapeutics position peaked at $276K in Q4 2025.
225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.